
Cipla Q2 results landed below Street expectations on Tuesday, with the Mumbai-based drugmaker reporting a 35% year-on-year fall in consolidated profit to ₹878 crore for the July–September quarter as a sharp drop in North American sales outweighed the best quarter its home market has ever delivered. Revenue from operations slipped 2.4% to ₹7,404 crore, while the EBITDA margin compressed by about 630 basis points to 18.7%.
The headline looks grim, but the sequential picture is kinder. Revenue grew 4% over the June quarter, margins widened by roughly 200 basis points from Q1, and management held on to its full-year targets. For investors, the real debate is whether a heavy US launch calendar in the second half can rebuild the earnings base that the company lost when a lucrative American generic faded from the portfolio.
Key takeaways
- Consolidated profit fell 35% to ₹878 crore from ₹1,351 crore, missing the CNBC-TV18 poll estimate of ₹949 crore.
- Revenue declined 2.4% to ₹7,404 crore against a Street estimate of about ₹7,498 crore, but rose 4% quarter-on-quarter.
- EBITDA dropped 26.7% to ₹1,388 crore; the 18.7% margin was slightly ahead of the 18.3% polled forecast.
- India revenue rose 12% to a record ₹3,516 crore, now about 48% of the business.
- North America revenue fell about 19% in rupee terms to ₹1,643 crore ($172 million), though it was up $10 million sequentially.
- FY27 EBITDA margin guidance of 18.5%–20% and a $1 billion US exit run-rate target were both retained.
Cipla Q2 results: the core numbers
The table below sets out the consolidated figures the company reported for the quarter ended September 30, 2026, alongside the year-ago period.
| Metric (₹ crore) | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 7,404 | 7,589 | −2.4% |
| EBITDA | 1,388 | 1,895 | −26.7% |
| EBITDA margin | 18.7% | 25.0% | −630 bps |
| Profit before tax | 1,177 | 1,854 | −36.5% |
| Net profit (company reported) | 878 | 1,351 | −35% |
| R&D spend | 423 (5.7% of sales) | — | — |
| One India revenue | 3,516 | ~3,140 | +12% |
| North America revenue | 1,643 ($172 mn) | ~2,030 | −19% |
| Net cash position | 9,823 | — | — |
One detail worth flagging: the statutory filing summarised by the exchange shows net profit of ₹851.51 crore and basic EPS of ₹10.86 (₹16.73 a year earlier). The ₹878 crore figure is the profit after tax number the company highlights in its investor release. Both point to a decline of more than a third from last year.
Why Cipla’s profit fell so sharply
The US base effect
The biggest drag was North America. A year ago, Cipla’s US business still carried meaningful income from a high-value generic cancer drug sold under limited competition. That window has since closed, and the replacement launches are only now arriving. In rupee terms, US revenue fell roughly 19%, and because American sales carry richer margins than most other markets, the hit to EBITDA was far larger than the hit to the top line.
Launch spending and a lumpy API book
Operating costs rose about 4% from the previous quarter as the company invested ahead of new product introductions. The small API and other segment also shrank sharply, down nearly 59% year-on-year to around ₹107 crore. Together, these factors explain why a modest dip in revenue translated into a steep fall in profit.
What improved from Q1
Not everything moved the wrong way. Margins recovered about 200 basis points from the June quarter, helped by a better product mix, and US revenue grew sequentially for another quarter. Profit also rose from ₹785.55 crore in Q1 FY27, suggesting the trough may already be behind the company.
India business powers ahead
Record domestic quarter
The domestic franchise was the clear bright spot. One India revenue climbed 12% to ₹3,516 crore, the highest quarterly figure in Cipla’s history. The branded prescription business grew around 15%, ahead of the wider market, with respiratory, urology, cardiac, anti-diabetes and dermatology portfolios all posting double-digit gains.
Trade generics and consumer health
Trade generics grew in the mid-single digits, which management linked to seasonality and cost factors, while more than 15 products were launched in the channel. Consumer health delivered high single-digit growth despite pricing pressure, and the company signalled it expects a return to double-digit expansion. For context, peers have shown a similar pattern this season — our coverage of Mankind Pharma’s Q2 results showed strong domestic demand too.
Africa and emerging markets
One Africa revenue was broadly flat at about ₹1,171 crore ($123 million). In South Africa, the private-market business grew 6.5% against market growth of 5%. Emerging Markets and Europe held steady at $101 million, which management described as resilient given the geopolitical backdrop.
Cipla Q2 results and the US pipeline: can launches fill the gap?
Advair and Ventolin
The most important near-term catalyst is generic Advair Diskus. Cipla secured US FDA approval during the quarter — its first dry powder inhaler cleared from its own US manufacturing network — and plans to launch in Q3. Management admitted the approval took a couple of months longer than expected. Its generic albuterol inhaler already holds a 22% share of the US metered-dose market, and supply ramp-ups on Ventolin-equivalent products are expected to add meaningfully.
Lanreotide and the biosimilar bet
On the cautious side, management does not expect lanreotide supplies to resume this financial year, and that product is excluded from the $1 billion annualised US exit-rate goal. Longer term, Cipla has tied up with China’s Qilu Pharmaceutical to commercialise a Keytruda (pembrolizumab) biosimilar in North America, with filing expected next year and launch targeted for 2029. Three more US launches — two respiratory and one peptide — are planned for FY27.
Guidance held steady
CEO Achin Gupta said the company remains focused on growth in its core businesses. The firm kept FY27 EBITDA margin guidance at 18.5% to 20%, pegged R&D at 6%–7% of revenue and expects an effective tax rate of 27%–27.5%. Management also expects margins to improve sequentially through the rest of the year. Full disclosures are available on Cipla’s investor relations page.
Market reaction: Cipla shares, Sensex, Nifty and flows
How the stock responded
Cipla announced its numbers during trading hours on October 27. The stock gave up early gains and ended about 1.9% lower near ₹1,330, roughly 14% above its 52-week low but still about 16% below its 52-week high. The muted move suggests investors had largely priced in a weak US quarter and are now focused on launch timing.
Sensex and Nifty backdrop
The broader market was flat. The Sensex closed at 73,598.67, down 8.08 points, and the Nifty 50 ended at 22,749.75, lower by 3.45 points, even as mid- and small-cap indices rallied and pharma stocks gained close to 2%. That followed Monday’s bounce, which we covered in our report on how the Sensex rebounded 483 points.
FPI and DII flows, crude and the rupee
Provisional exchange data showed foreign portfolio investors net buyers of about ₹4,240 crore on October 27, while domestic institutions sold roughly ₹1,250 crore — a rare reversal after weeks of heavy foreign outflows. Brent crude stayed elevated near $116 a barrel with Strait of Hormuz flows still well below normal, and the rupee hovered around 95.3 per dollar. A weak rupee is a mild tailwind for exporters such as Cipla, since dollar revenue converts into more rupees.
Asia and the Fed overhang
Across Asia, Japan’s Nikkei and South Korea’s Kospi rose on Tuesday while mainland Chinese indices fell. GIFT Nifty pointed to a flat start for Wednesday as traders wait for the US Federal Reserve decision, which arrives after Indian hours. Our preview of the central bank super week explains why a hawkish tone could pressure the rupee and foreign flows. Wednesday also brings the Jio Platforms listing, which could pull liquidity across large caps.
How Cipla compares with this earnings season
Cipla’s quarter contrasts with strong prints elsewhere. Bajaj Auto’s Q2 profit rose 35% on export momentum, while L&T posted a 33% jump backed by record orders. Among drugmakers, the split is clear: firms leaning on India are growing steadily, while those with large US generic exposure are working through price erosion and product cycles. For a wider view of the week ahead, see our stock market outlook.
What to watch next
- Advair launch timing: confirmation of a Q3 US launch and early market-share data will be the single biggest swing factor for H2 earnings.
- US quarterly run-rate: track whether North America revenue climbs meaningfully above $172 million in Q3 toward the $1 billion annualised target.
- Margin trajectory: watch whether EBITDA margins move toward the middle of the 18.5%–20% guidance band.
- India momentum: sustained double-digit domestic growth and a pickup in trade generics would cushion any US delay.
- Macro signals: the Fed decision, rupee moves around 95 per dollar and FPI flows will shape sentiment for export-heavy pharma stocks.
- Broker revisions: expect earnings estimate cuts for FY27 to be weighed against higher FY28 forecasts tied to new launches.
FAQ
What were Cipla’s Q2 FY27 results?
Cipla reported consolidated profit of ₹878 crore, down 35% year-on-year, on revenue of ₹7,404 crore, down 2.4%. EBITDA fell 26.7% to ₹1,388 crore with an 18.7% margin.
Why did Cipla’s profit decline in Q2?
North American revenue fell about 19% in rupee terms as a high-margin US product lost its limited-competition advantage, while launch-related costs rose ahead of new product introductions.
Did Cipla beat or miss estimates?
Profit and revenue missed estimates, while EBITDA and margin came in slightly ahead of the CNBC-TV18 poll.
Has Cipla changed its FY27 guidance?
No. The company kept its EBITDA margin guidance at 18.5%–20% and its target of a $1 billion annualised US revenue run-rate by the end of FY27.
How did Cipla shares react to the Q2 results?
Shares slipped about 1.9% to around ₹1,330 on October 27, giving up intraday gains as investors weighed the US slowdown against the record India quarter.
This article is for informational purposes only and does not constitute investment advice.

